02241nas a2200241   4500000000100000008004100001653001500042653001200057653000800069653001100077653001100088100002000099700001600119700001900135700001800154700002500172700002100197245005700218856006200275050002300337520162500360022001401985       2014                            d10aLeukocytes10aleprosy10aBCG10aAnergy10aMurene1 aJuarez-Ortega M1 aHernandez V1 aArce-Paredes P1 aVillanueva EB1 aAguilar-Santelises M1 aRojas-Espinosa O00aInduction and treatment of anergy in murine leprosy.  uhttp://onlinelibrary.wiley.com/doi/10.1111/iep.12108/epdf  aJUAREZ-ORTEGA 20143 a<p>Leprosy is a disease consisting of a spectrum of clinical, bacteriological, histopathological and immunological manifestations. Tuberculoid leprosy is frequently recognized as the benign polar form of the disease, while lepromatous leprosy is regarded as the malignant form. The different forms of leprosy depend on the genetic and immunological characteristics of the patient and on the characteristics of the leprosy bacillus. The malignant manifestations of lepromatous leprosy result from the mycobacterial-specific anergy that develops in this form of the disease. Using murine leprosy as a model of anergy in this study, we first induced the development of anergy to Mycobacterium lepraemurium (MLM) in mice and then attempted to reverse it by the administration of dialysable leucocyte extracts (DLE) prepared from healthy (HLT), BCG-inoculated and MLM-inoculated mice. Mice inoculated with either MLM or BCG developed a robust cell-mediated immune response (CMI) that was temporary in the MLM-inoculated group and long-lasting in the BCG-inoculated group. DLE were prepared from the spleens of MLM- and BCG-inoculated mice at the peak of CMI. Independent MLM intradermally-inoculated groups were treated every other day with HLT-DLE, BCG-DLE or MLM-DLE, and the effect was documented for 98&nbsp;days. DLE administered at a dose of 1.0&nbsp;U (1&nbsp;×&nbsp;10(6) splenocytes) did not affect the evolution of leprosy, while DLE given at a dose of 0.1&nbsp;U showed beneficial effects regardless of the DLE source. The dose but not the specificity of DLE was the determining factor for reversing anergy.</p>
  a1365-2613